Skip to content
An Initiative of AVAC
Search
Back to Events

New WHO Guidance on Lenacapavir for Prevention and HIV Testing for Long-Acting PrEP

Thursday28August
11:00 - 12:00 GMT
Virtual

This 60-minute webinar is intended for communities, providers, policy makers and advocates for PrEP, HIV prevention and HIV testing. We will provide an overview of the key takeaways and new guidance from newly released Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis.

This is the first webinar in a three-part series:

  • Part 2 on 4 September 2025 focus on HIV testing (in partnership with PSI)
  • Part 3 will focus on e-training for PrEP providers (in partnership with Jhpiego)

Further details about these webinars will be shared soon!

Topic(s): Normative Guidance/Policies, Service Delivery, Testing

Product(s): Injectable Prep, Lenacapavir

Source(s): WHO

Register Now

Featured Resources

External Link

The WHO and Jhpiego Provider Training Toolkit on Use of Oral and Long-Acting HIV Pre-Exposure Prophylaxis (PrEP)

This toolkit is designed to help clinicians develop knowledge and skills to provide multiple HIV PrEP methods. The toolkit includes resources for oral PrEP, long-acting cabotegravir (CAB-LA), dapivirine vaginal ring (DVR), and long-acting lenacapavir (LEN).
External Link

Long-Acting PrEP Market Assessment for Key Populations: Global access and readiness report (2025)

This market assessment supports countries, donors, implementing partners, and advocates in making informed decisions about the introduction, scale-up, and equitable delivery of long-acting PrEP among key populations and other priority groups.
External Link

Global Forecast of Long-Acting PrEP Need for Key Populations (2025–2030)

This first-of-its-kind forecast estimates: 11.16 million person-years of PrEP needed annually by 2030 among MSM, TGW, FSW, and PWID Uptake scenarios for CAB-LA, LEN, and oral monthly PrEP Forecasts segmented by region, population group, and product Use it to guide: Procurement planning, donor alignment, and national scale-up targets.
External Link

Guidelines on Lenacapavir for HIV Prevention and Testing Strategies for Long-Acting Injectable Pre-Exposure Prophylaxis

In this guideline, WHO recommends an offering long-acting injectable lenacapavir (LEN) as an additional HIV prevention choice, as part of combination HIV prevention approaches. LEN, administered twice a year as PrEP, has been shown to be highly effective at reducing the risk of HIV acquisition. In this guideline, WHO also recommends using HIV rapid diagnostic…
Spreadsheet

2024 Q4 Global PrEP Tracker

AVAC’s Global PrEP Tracker offers two views on PrEP uptake around the world. Visit data.prepwatch.org for a dynamic map-based tool to explore trends in oral PrEP use globally as countries introduce and scale up PrEP programs. For insights on the full scope of PrEP use around the world, the PrEP Tracker as a spreadsheet offers…
External Link

HIVR4P 2024 Knowledge Toolkit

The HIVR4P 2024 Knowledge Toolkit highlights important scientific advancements and innovative research across key thematic areas presented at the HIVR4P 2024 conference. Thematic areas include the PURPOSE 2 trial of long-acting lenacapavir for PrEP, data on the three-month dapivirine vaginal ring, and early evidence on offering a choice of PrEP methods.
External Link

Interest in Injectable and Oral PrEP for HIV Prevention Among Women and Men Who Inject Drugs

This article from Journal of Addiction Medicine examines interests and concerns around use of oral and injectable PrEP amongst people who inject drugs in the United States.
Document

PrEP Booklet of Frequently Asked Questions (FAQs): A Peer Outreach Worker Tool

This tool was developed to be used by peer outreach workers, peer educators, and other community-based health providers to help provide comprehensive information about pre-exposure prophylaxis (PrEP) to key population peers.
Document

Long-Acting PrEP for Key Populations: Considerations for Implementation

This document is intended for program implementers, advocates, policymakers, and other stakeholders who influence the rollout of long-acting options for pre-exposure prophylaxis (PrEP). It highlights some of the considerations for long-acting PrEP implementation for key population individuals.
External Link

Understanding the Drivers of CAB PrEP Uptake and Use among Women in sub-Saharan Africa to Build Demand for New PrEP Methods

This article from Current HIV/AIDS Reports reviews facilitators and barriers to use of injectable cabotegravir (CAB) for PrEP by women in sub-Saharan Africa.